Table 1.
The relationship between PIV and clinicopathological characteristics in the whole cohort.
| Characteristic | Total (N = 1,312) | High-PIV group (N = 152) | Low-PIV group (N = 1,160) | p |
|---|---|---|---|---|
| Age (years), median (IQR) | 48 (41–57) | 46 (40–55) | 48 (41–57) | 0.127 |
| Tumor stage | 0.292 | |||
| T1 | 467 (35.6) | 52 (34.2) | 415 (35.8) | |
| T2 | 719 (54.8) | 79 (52.0) | 640 (55.2) | |
| T3 | 65 (5.0) | 10 (6.6) | 55 (4.7) | |
| T4 | 61 (4.6) | 11 (7.2) | 50 (4.3) | |
| Node stage | 0.178 | |||
| N0 | 687 (52.4) | 69 (45.4) | 618 (53.3) | |
| N1 | 345 (26.3) | 42 (27.6) | 303 (26.1) | |
| N2 | 163 (12.4) | 26 (17.1) | 137 (11.8) | |
| N3 | 117 (8.9) | 15 (9.9) | 102 (8.8) | |
| Clinical stage | – | |||
| I | 317 (24.2) | 30 (19.7) | 287 (24.7) | |
| II | 679 (51.7) | 73 (48.0) | 606 (52.3) | |
| III | 316 (24.1) | 49 (32.3) | 267 (23.0) | |
| BMI kg/m2, median (IQR) | 23 (20.8–25.2) | 23.4 (21.0–25.7) | 22.9 (20.8–25.1) | 0.158 |
| Histological type | 0.902 | |||
| Invasive ductal carcinoma | 1,109 (84.5) | 129 (84.9) | 980 (84.5) | |
| Others | 203 (15.5) | 23 (15.1) | 180 (15.5) | |
| ER status | 0.020* | |||
| Positive | 942 (71.8) | 97 (63.8) | 845 (72.8) | |
| Negative | 370 (28.2) | 55 (36.2) | 315 (27.2) | |
| PR status | 0.413 | |||
| Positive | 842 (64.2) | 93 (61.2) | 749 (64.6) | |
| Negative | 470 (35.8) | 59 (38.8) | 411 (35.4) | |
| HER-2 status | 0.975 | |||
| Positive | 387 (29.5) | 45 (29.6) | 342 (29.5) | |
| Negative | 925 (70.5) | 107 (70.4) | 818 (70.5) | |
| Ki-67 | 0.349 | |||
| >14% | 575 (43.8) | 72 (47.4) | 503 (43.4) | |
| ≤14% | 737 (56.2) | 80 (52.6) | 657 (56.6) | |
| Adjuvant chemotherapy | 0.285 | |||
| Yes | 1,066 (81.3) | 111 (73.0) | 955 (82.3) | |
| No | 246 (18.7) | 41 (27.0) | 205 (17.7) | |
| Radiotherapy | 0.761 | |||
| Yes | 350 (26.7) | 43 (28.3) | 307 (26.5) | |
| No | 962 (73.3) | 109 (71.7) | 853 (73.5) | |
| Endocrine therapy | 0.818 | |||
| Yes | 680 (51.8) | 79 (52.0) | 601 (51.8) | |
| No | 632 (48.2) | 73 (48.0) | 559 (48.2) | |
| Target therapy | 0.485 | |||
| Yes | 95 (7.2) | 15 (9.9) | 80 (6.9) | |
| No | 1,217 (92.8) | 137 (90.1) | 1,080 (93.1) | |
| PLT (109/L), median (IQR) | 225 (190.0–265.0) | 272 (236.9–310.5) | 220.5 (186.0–255.2) | – |
| NE (109/L), median (IQR) | 3.7 (2.9–4.6) | 5.3 (4.4–7.0) | 3.5 (2.8–4.3) | – |
| MONO (109/L), median (IQR) | 0.3 (0.2–0.4) | 0.5 (0.4–0.6) | 0.3 (0.2–0.4) | – |
| LY (109/L), median (IQR) | 1.9 (1.6–2.3) | 1.63 (1.4–2.2) | 1.91 (1.6–2.3) | – |
PIV low group (PIV ≤ 310.2) and PIV high group (PIV > 310.2).
PIV, pan-immune-inflammation value; IQR, interquartile range; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; PLT, platelet count; NE, neutrophil count; MONO, monocyte count; LY, lymphocyte count.
*p < 0.05.